CEL-SCI to expand Multikine Phase III trial in head and neck cancer
Links shared publicly online about this topic.
- 0total visits
CEL-SCI to expand Multikine Phase III trial in head and neck cancer
View full resource at news-medical.net
Tags: Cancer, Head and Neck Cancer, Arthritis, Clinical Trial, News
Most Recently Shared on December 28, 2011 at 9:38 am By:
H1N1 Swine Flu News: CEL-SCI to expand Multikine Phase III trial in head and neck cancer: CEL-SCI Corporation is... http://t.co/pT4HEyhz
Also Shared By:
Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer
news-medical.net — “CEL-SCI Corporation announced today that its Taiwanese partner, Orient Europharma, has concluded the Site Initiation Visit for the first Taiwanese clinical center in CEL-SCI's Phase III clinical trial for Multikine, the Company's flagship cancer immunotherapy. The first center is called Shin Kong Wu Ho-Su Memorial Hospital and is located in Taipei, Taiwan.” View full resource at news-medical.net
Most Recently Shared on June 24, 2011 at 8:40 am By:
H1N1 Swine Flu News: Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer... http://twurl.nl/n6053j
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Hungary
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncol” View full resource at medicalnewstoday.com
Most Recently Shared on June 14, 2011 at 3:05 pm By:
MNT Ear, Nose Throat Health News
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Hungary http://mnt.to/3X9Q #entnews
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Russia
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, in Russia at the State Budg” View full resource at medicalnewstoday.com
Most Recently Shared on May 20, 2011 at 12:05 pm By:
MNT Clinical Trials Health News
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Russia http://mnt.to/3W8Z #clinicaltrials
CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada
news-medical.net — “CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.” View full resource at news-medical.net
Most Recently Shared on May 18, 2011 at 2:37 pm By:
H1N1 Swine Flu News: CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada: CEL-SCI C... http://twurl.nl/3pgub6
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Poland
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the Centrum Onkologii -” View full resource at medicalnewstoday.com
Most Recently Shared on May 16, 2011 at 10:05 am By:
MNT Ear, Nose Throat Health News
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In Poland http://mnt.to/3VTk #entnews
New Jersey Medical School And Veteran Affairs Medical Center Is Ready To Commence Enrollment For Phase III Trial Of Multikine In Head And Neck Cancer
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced today that, following completion of a successful site initiation visit, the New Jersey Medical School and Veterans Affairs Medical Center is ready to” View full resource at medicalnewstoday.com
Most Recently Shared on May 10, 2011 at 12:05 pm By:
MNT Ear, Nose Throat Health News
New Jersey Medical School And Veteran Affairs Medical Center Is Ready To Commence Enrollment For Phase III Trial Of Mu... http://mnt.to/3VDx
CEL-SCI Corporation Receives Government Approval In Poland To Commence Phase III Clinical Trial Of Multikine In Head And Neck Cancer
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has received approval to begin enrollment of patients in its Phase III clinical trial of Multikine® from the Polish Minister of Hea” View full resource at medicalnewstoday.com
Most Recently Shared on May 5, 2011 at 12:05 pm By:
MNT Clinical Trials Health News
CEL-SCI Corporation Receives Government Approval In Poland To Commence Phase III Clinical Trial Of Multikine In Head A... http://mnt.to/3Vsz
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In India
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced today that it has commenced its global Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the Meenakshi Mission Ho” View full resource at medicalnewstoday.com
Most Recently Shared on May 3, 2011 at 5:05 pm By:
MNT Ear, Nose Throat Health News
CEL-SCI Commences Phase III Clinical Trial In Head And Neck Cancer In India http://mnt.to/3Vm4 #entnews
CEL-SCI Corporation Receives Israeli Government Approval To Commence Phase III Clinical Trial Of Multikine In Head And Neck Cancer
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced today that the State of Israel's Ministry of Health has given approval to begin enrollment of subjects for a Phase III clinical trial of Multikine&re” View full resource at medicalnewstoday.com
Most Recently Shared on March 31, 2011 at 12:05 pm By:
MNT Clinical Trials Health News
CEL-SCI Corporation Receives Israeli Government Approval To Commence Phase III Clinical Trial Of Multikine In Head And... http://mnt.to/3SYV
CEL-SCI Corporation Receives Government Approval From Ukraine To Commence Phase III Clinical Trial Of Multikine In Head And Neck Cancer
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clini” View full resource at medicalnewstoday.com
Most Recently Shared on December 17, 2010 at 1:30 pm By:
MNT Ear, Nose Throat Health News
CEL-SCI Corporation Receives Government Approval From Ukraine To Commence Phase III Clinical Trial Of Multikine In Hea... http://mnt.to/3Pdm
CEL-SCI Corporation Receives Government Approval From Taiwan To Commence Phase III Clinical Trial Of Multikine In Head And Neck Cancer
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced it has received governmental approval from the Taiwanese Department of Health to begin enrollment of subjects for a Phase III clinical trial of Multi” View full resource at medicalnewstoday.com
Most Recently Shared on December 6, 2010 at 2:05 pm By:
MNT Ear, Nose Throat Health News
CEL-SCI Corporation Receives Government Approval From Taiwan To Commence Phase III Clinical Trial Of Multikine In Head... http://mnt.to/3NB8
CEL-SCI Completes Global Investigator Meeting In Preparation For Enrollment And Treatment Of Patients In Phase III Head And Neck Cancer Trial
medicalnewstoday.com — “CEL-SCI Corporation (NYSE AMEX: CVM) announced that the Company held a clinical investigator meeting during the week of November 14th for its Phase III clinical trial of Multikine®, the Compan” View full resource at medicalnewstoday.com
Most Recently Shared on November 25, 2010 at 10:55 am By:
Surgery Center of the Main Line. He was appointed by Governor
Rendell to be an advisor on the Medical Liability Task Force and is
Chairman of the Otolaryngology section and member of the Medical
Executive Committee at Phoenixville Hospital.
Dr. Broker has been recognized as “Top Doc” by Main Line Today magazine consistently since 2003." /> Dr Brian Broker - ENT and Allergy Surgeon, ENT Doctor, Physician, Active Health Library, and Doctor
http://bit.ly/gKyrKh Promising drug trial to help immune system defeat cancer in mouth to begin. Prelim results w 33% improvement survival.
North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer
news-medical.net — “CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights a” View full resource at news-medical.net
Most Recently Shared on September 13, 2010 at 7:33 pm By:
North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer: CEL-SCI Corp... http://bit.ly/bqhYj7
Advertisement
News-Medical.Net
@Arthritis_News
Arthritis News: Orient Europharma to initiate CEL-SCI's Multikine Phase III trial in head and neck cancer: CEL-S... http://bit.ly/iOeris
1 year ago...